Bio-Rad Laboratories Class A
469 hedge funds and large institutions have $7.19B invested in Bio-Rad Laboratories Class A in 2023 Q2 according to their latest regulatory filings, with 51 funds opening new positions, 155 increasing their positions, 194 reducing their positions, and 84 closing their positions.
1.59% less ownership
Funds ownership: 78.33% → 76.74% (-1.6%)
7% less funds holding
Funds holding: 504 → 469 (-35)
20% less repeat investments, than reductions
Existing positions increased: 155 | Existing positions reduced: 194
22% less capital invested
Capital invested by funds: $9.2B → $7.19B (-$2.01B)
31% less funds holding in top 10
Funds holding in top 10: 13 → 9 (-4)
39% less first-time investments, than exits
New positions opened: 51 | Existing positions closed: 84
46% less call options, than puts
Call options by funds: $28.9M | Put options by funds: $53.7M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAM
Southeastern Asset Management
Memphis,
Tennessee
|
+$132M |
| 2 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$46.2M |
| 3 |
Select Equity Group
New York
|
+$40.9M |
| 4 |
HP
Hound Partners
New York
|
+$39.5M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$38.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
A
AustralianSuper
Melbourne,
Australia
|
-$122M |
| 2 |
Millennium Management
New York
|
-$81.7M |
| 3 |
Los Angeles Capital Management
Los Angeles,
California
|
-$69.4M |
| 4 |
SSA
Schonfeld Strategic Advisors
New York
|
-$67.9M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$51.1M |
BIO Hedge Fund Activity: Q2 2023 in Review
469 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Bio-Rad Laboratories Class A (BIO) for Q2 2023, worth a combined $7.19B — down 22% from $9.2B a quarter earlier.
Sellers outnumbered buyers: 84 funds closed out of BIO and 51 opened new positions — a net loss of 33 holders — while 194 trimmed existing stakes and 155 added.
The largest buyer was Southeastern Asset Management, opening a new position worth an estimated $132M. The largest seller was AustralianSuper, exiting entirely with an estimated $122M sold.
- 469 institutional investors held Bio-Rad Laboratories Class A (BIO) as of Q2 2023, down from 504 in Q1 2023.
- Funds reported $7.19B of Bio-Rad Laboratories Class A stock for Q2 2023, down 22% quarter-over-quarter.
- 51 funds opened new Bio-Rad Laboratories Class A positions in Q2 2023 and 84 closed out, a net change of -33 holders.
- The largest Bio-Rad Laboratories Class A buyer in Q2 2023 was Southeastern Asset Management, an estimated $132M added.
- The largest Bio-Rad Laboratories Class A seller in Q2 2023 was AustralianSuper, an estimated $122M sold.
Based on aggregated 13F filings for Q2 2023.